SEC Form 4 · accession 0001628280-26-055700
Crinetics Pharmaceuticals, Inc. · CRNX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Richard Scott Struthers
Officer — President & CEO · Director
Period of report
Aug 7, 2026
Accepted (ET)
Aug 11, 2026 · 4:11 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001658247
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Aug 7, 2026 | M | 3,969 | $25.19 | A | 408,747 | D | |
| Common Stock | Aug 7, 2026 | M | 4,422 | $22.61 | A | 413,169 | D | |
| Common Stock | Aug 7, 2026 | M | 6,542 | $15.29 | A | 419,711 | D | |
| Common Stock | Aug 7, 2026 | M | 4,995 | $20.02 | A | 424,706 | D | |
| Common Stock | holding | — | — | — | 136,805 | I | By Family Trust 1 | |
| Common Stock | holding | — | — | — | 106,000 | I | By Family Trust 2 | |
| Common Stock | holding | — | — | — | 110,000 | I | By Family Trust 3 | |
| Common Stock | holding | — | — | — | 100,000 | I | By Family Trust 4 | |
| Common Stock | holding | — | — | — | 111,100 | I | By Family Trust 5 | |
| Common Stock | holding | — | — | — | 111,100 | I | By Family Trust 6 | |
| Common Stock | holding | — | — | — | 111,100 | I | By Family Trust 7 | |
| Common Stock | holding | — | — | — | 111,100 | I | By Family Trust 8 | |
| Common Stock | holding | — | — | — | 1,000 | I | By Spouse | |
| Common Stock | holding | — | — | — | 80,000 | I | By Charitable Trust |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1 | $25.19 | Aug 7, 2026 | M | 3,969 | D | — | Mar 8, 2029 | Common Stock | 3,969 | 172,281 | D |
| Stock Option (Right to Buy)F2 | $22.61 | Aug 7, 2026 | M | 4,422 | D | — | Feb 24, 2030 | Common Stock | 4,422 | 195,578 | D |
| Stock Option (Right to Buy)F3 | $15.29 | Aug 7, 2026 | M | 6,542 | D | — | Feb 26, 2031 | Common Stock | 6,542 | 259,058 | D |
| Stock Option (Right to Buy)F4 | $20.02 | Aug 7, 2026 | M | 4,995 | D | — | Feb 29, 2032 | Common Stock | 4,995 | 244,205 | D |
Explanation of responses
- F11/48th of the shares subject to the option vested monthly.
- F21/48th of the shares subject to the option vested on March 24, 2020, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.
- F31/48th of the shares subject to the option vested on March 26, 2021, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.
- F41/48th of the shares subject to the option vested on March 31, 2022, and 1/48th of the shares subject to the option vested monthly thereafter, subject to the Reporting Person's continued employment with the Issuer on each such vesting date.